Introduction {#sec0001}
============

There is an increase in the incidence of brain metastases in soft tissue and bone sarcomas due to new chemotherapeutic and radiotherapeutic treatments that prolong survival through systemic disease control but without effective intracranial control [@bib0001], [@bib0002], [@bib0003]. Mean time of brain metastasis from initial diagnosis is approximately 20-30 months [@bib0004].

Brain metastases are rare in osteosarcoma and lung tumor emboli invading the brain is the main cause of metastases [@bib0005]. Yonemoto et al recommended performing brain imaging periodically in patients with known active pulmonary metastasis [@bib0006]. Similarly to osteosarcoma metastases to the lungs, brain lesions are characterized by large calcifications.

The primary tumors reported to be responsible for calcified brain metastases are squamous cell carcinoma of the lung, adenocarcinoma of the lung, breast adenocarcinoma, mediastinal sarcoma, squamous cell carcinoma of the cervix, adenocarcinoma of the pancreas, non-Hodgkin\'s lymphoma, osteosarcoma and mucinous colorectal, and ovarian adenocarcinomas [@bib0007].

We report the clinical course of a 23-year-old patient with a history of femoral osteosarcoma, who was diagnosed with brain metastasis. CT scan showed a unique calcified lesion inside the left cerebellar parenchyma, mimicking an osseous lesion.

Case presentation {#sec0002}
=================

A 20-year-old male was diagnosed with high-grade osteoblastic osteosarcoma of the right femur, in October 2016. He received neoadjuvant chemotherapy according to MAP protocol (high-dose methotrexate, adriamycin, cisplatin) in the first medical oncology clinic of Saint-Savvas Cancer Hospital (Athens, Greece) between August and October 2016. In October 2016 he underwent surgery and histological examination revealed osteosarcoma with \<90% necrosis. He received adjuvant treatment per protocol, combined with mifamurtide, which was maintained until November 2017.

In March 2018 he was diagnosed with solitary lung mass. He underwent lung metastasectomy and histological examination confirmed metastasis from high-grade osteosarcoma. We did not administer to the patient any systemic treatment, in line with the sarcoma tumor board decision for a close follow-up. Six months later imaging revealed a controlateral lung lesion, as well as a left pelvic mass. We opted again for surgical management of the 2 metastases. Therefore the patient underwent lung metastasectomy followed by resection of the pelvic mass. Subsequently, he received 3 cycles of ifosfamide/etoposide chemotherapy. Imaging reevaluation showed unfortunately progression of the disease, with multiple lung nodules. Gemcitabine/docetaxel was then administered as third-line chemotherapy with no efficacy and finally topotecan/cyclophosphamide. CT scan of thorax and abdomen after the third cycle revealed progressive disease in the lungs ([Fig. 1](#fig0001){ref-type="fig"}), as well as new renal metastases.Fig. 1Thoracic CT scan (axial view) showing multiple partially calcified lung metastases from osteosarcoma.Fig 1

One month later he visited the oncology clinic with headache and a slight unsteady gait. A brain CT scan was performed showing a left cerebellar metastasis of 2.3 cm in size with perilesional edema ([Fig. 2](#fig0002){ref-type="fig"}). The patient had a good performance status and neurological symptoms resolved with dexamethasone treatment. We opted to administer off-label cabozantinib, a tyrosine kinase inhibitor (TKI) which was recently reported to have some activity in advanced bone sarcomas. Radiation therapy to the cerebral tumor was not proposed, due to the relative radioresistance of osteosarcoma. Therefore he started cabozantinib 60 mg per day at the end of July 2019, without any complications except for mild transaminitis. Symptoms associated with cerebral metastasis did not recur, despite a rapid cortisone tapering. However, the patient died 2 months later due to respiratory failure in the context of progressive disease in the lungs.Fig. 2A brain CT scan (axial and coronal view) was performed and revealed a solitary space occupying lesion, 2.3 cm in size, in the left cerebellar region with large intralesional central calcification and perilesional edema that was suggestive of metastatic deposit of osteosarcoma.Fig 2

Discussion {#sec0003}
==========

Cerebral metastases from soft tissue or bone sarcomas are not common and therefore brain imaging is not systematically performed. Their incidence is approximately 1%-8% \[[@bib0003],[@bib0008],[@bib0009]\]. In the largest adult series (246 patients), published by the French Sarcoma Group, osteosarcoma represented 6% of cases, whereas more common soft tissue histotypes like leiomyosarcoma represented the majority of cases [@bib0010]. Pediatric studies have reported a higher incidence of brain metastases from osteosarcoma, compared to other histologies [@bib0001].

Radiological findings of osteosarcoma brain metastases are unique and characterized by large calcifications. Both supratentorial and infratentorial localizations have been reported \[[@bib0011],[@bib0012]\]. Our patient exhibited a typical image of a left cerebellar mass with large intralesional central calcification in brain CT scan. He developed also metastases to both kidneys, another rare location for osteosarcoma.

Very sparse data exist regarding the clinical course and management of brain metastases from osteosarcoma and come mainly from case-reports or small retrospective series [@bib0008], [@bib0009], [@bib0010], [@bib0011], [@bib0012]. Most patients are already diagnosed with metastases in other sites, more commonly the lungs. Despite the poor prognosis of brain metastases, aggressive multimodality treatment has been reported to prolong survival of these patients [@bib0004].

Surgical management has traditionally been reported as the main treatment modality for sarcoma brain metastasis \[[@bib0006],[@bib0013], [@bib0014], [@bib0015]\]. This is based to the evidence originating from some studies of osteosarcoma lung metastases, in which a survival benefit is reported [@bib0016]. Surgical resection of osteosarcoma brain metastases has led in some cases to long-term disease control and survival \[[@bib0006],[@bib0011]\].

Evidence for the use of radiation therapy is inconclusive. It has been used in some cases of soft tissue and bone sarcoma metastases \[[@bib0005],[@bib0017]\]. According to the French retrospective series, local treatments including surgery and radiation therapy seem beneficial in terms of survival [@bib0010]. This approach needs evaluation in the context of prospective trials. We did not deliver radiation therapy to our patient, because osteosarcoma is not considered a radiosensitive sarcoma histotype. In addition he experienced disease progression in the lungs, not amenable to local treatment.

Systemic therapy is the mainstay of treatment for metastatic sarcoma. As for other primary tumors, the question of intracranial efficacy of the different drugs is posed. TKIs represent a relatively new therapeutic class in the armamentarium of bone sarcomas. Sorafenib, regorafenib, lenvatinib, and cabozantininb were tested in phase 2 trials of advanced osteosarcoma and clinically relevant efficacy was found [@bib0018], [@bib0019], [@bib0020], [@bib0021]. Cabozantinib yielded the most positive result, with a median progression-free survival of 6.2 months. Our patient was heavily pretreated and received off-label cabozantinib. Despite corticoid tapering, he did not experience any recurrence of neurological symptoms, suggesting a possible control of intracranial metastasis. TKIs like cabozantinib could be an effective treatment for cerebral metastases and warrant further evaluation.

In conclusion, we present an interesting radiological image of osteosarcoma metastasis to the left cerebellar parenchyma in a young male. Our case illustrates a clinical scenario of calcified brain metastases. Although sarcoma metastatic to the brain is uncommon, clinicians should be aware of this condition and request appropriate investigations.
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